Invivyd (NASDAQ:IVVD) CFO Sells 18,425 Shares

Invivyd, Inc. (NASDAQ:IVVD) CFO William Duke sold 18,425 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total value of $15,477.00. Following the transaction, the chief financial officer directly owned 168,937 shares in the company, valued at approximately $141,907.08. The trade was a 9.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Stock Up 17.2%

Shares of Invivyd stock traded up $0.13 during trading on Tuesday, reaching $0.87. The company’s stock had a trading volume of 7,732,095 shares, compared to its average volume of 3,061,089. The company has a market cap of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. Invivyd, Inc. has a 1-year low of $0.48 and a 1-year high of $3.07. The company has a 50-day simple moving average of $0.77 and a two-hundred day simple moving average of $1.23.

Invivyd (NASDAQ:IVVD) last announced its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The business had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. As a group, analysts anticipate that Invivyd, Inc. will post -0.52 earnings per share for the current year.

Institutional Trading of Invivyd

Several large investors have recently made changes to their positions in IVVD. OMERS ADMINISTRATION Corp increased its stake in shares of Invivyd by 9.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 106,900 shares of the company’s stock worth $139,000 after acquiring an additional 8,800 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Invivyd by 54.3% during the first quarter. Bank of New York Mellon Corp now owns 27,184 shares of the company’s stock worth $35,000 after purchasing an additional 9,568 shares during the last quarter. Courier Capital LLC acquired a new position in Invivyd during the fourth quarter valued at $25,000. Bronte Capital Management Pty Ltd. acquired a new position in Invivyd during the fourth quarter valued at $27,000. Finally, DRW Securities LLC purchased a new stake in Invivyd in the fourth quarter valued at $27,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IVVD. Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. HC Wainwright reissued a “buy” rating on shares of Invivyd in a research report on Tuesday. BTIG Research restated a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.